1. Background {#s0005}
=============

Physical activity (PA) is defined as any bodily movement that requires an energy expenditure above resting ([@b0055]). Regular PA has been associated with the prevention and treatment of a range of diseases, such as cardiovascular disease ([@b0170]), type II diabetes ([@b0065]), osteoporosis ([@b0225], [@b0315]) and breast cancer ([@b0125]). However, 31% of adults are inactive, making physical inactivity a major international public health concern ([@b0135]).

Although accelerometers are capable of measuring raw acceleration at high sampling frequencies, the majority of studies rely on cut-points to classify PA intensities. Consequently, a growing body of calibration studies has led to a range of cut-points to classify PA intensities in adults ([@b0100], [@b0360]), with little consensus as to the optimal cut-points or their applicability to populations other than those in which they were developed. Indeed, inter-study comparisons and cut-point generalisability are limited by a lack of standardisation of methodologies. Specifically, considerable variation in calibration protocols has arisen due, at least in part, to the progression from uni- to tri-axial accelerometry, the growing range of accelerometer models available and the broad range of configuration options (e.g., epoch, frequency). Furthermore, inter-study discrepancies in moderate-to-vigorous physical activity (MVPA) cut-points may also be attributable to variations in the criterion measures adopted and to the specific calibration protocol utilised; calibration protocols may range from a laboratory-based treadmill or walking protocol ([@b0095]) to a field-based protocol ([@b0275]), or a combination of both ([@b0235]). Finally, the statistical approach used to translate activity counts into thresholds aligned with the criterion varies considerably between studies, with little evidence currently available regarding the comparability of different statistical methods.

A key question that remains to be addressed is the applicability of current calibration protocols to clinical populations. Specifically, physiological and biomechanical differences, common in many chronic conditions such as Chronic Obstructive Pulmonary Disease and Parkinson's Disease (PD), may result in a higher cost of breathing or daily living activities and altered resting metabolic rate (RMR) demands ([@b0035], [@b0120], [@b0165], [@b0285], [@b0300], [@b0330]). Subsequently, cut-points developed for healthy populations are unlikely to appropriately reflect the activity levels of those with such diseases ([@b0215], [@b0320]) and population-specific cut-points, accounting for condition-specific energy expenditure (EE), are warranted. For example, applying cut-points developed on healthy populations was shown to be inappropriate for some clinical conditions, such as chronic stroke ([@b0320]) and type II diabetes ([@b0215]). However, whilst accelerometry seems to be valid for some clinical conditions ([@bib396]), the development of population-specific cut-points was shown to improve the accuracy of the PA measurement in multiple sclerosis (MS) and in obese populations ([@b0370]). Given this lack of consensus, a synthesis of currently available cut-points, and calibration protocols, in clinical populations could afford valuable information for future clinical physical activity research.

Therefore, the aim of this systematic review was to describe current protocols utilised for the calibration of accelerometry to estimate MVPA thresholds for adult clinical populations. Secondly, the purpose was to provide recommendations for future studies seeking to calibrate accelerometers for clinical conditions in adults.

2. Methods {#s0010}
==========

This review was performed according to the Preferred Reporting Items for Systematic Review and Meta-Analysis statement ([@b0175], [@b0240]), and registered on the International Prospective Register of Systematic Review (PROSPERO registration ID: CRD42016053880).

3. Search methods {#s0015}
=================

The search was performed between March and July 2017 using six databases (PubMed, SPORTDiscus, ScienceDirect, Scopus, ISI Web of Knowledge, Wiley Online Library). Further details regarding the full search can be found on the [Web-Appendix](#s0115){ref-type="sec"}. The protocol was revised by an experienced librarian and a pilot was performed to assure feasibility. The search terms were in accordance with the 2017 Medical Subject Headings and were inserted as keywords to all the databases as follows: acceleromet\*; acceleromet\* AND (validation OR calibration); acceleromet\* AND physical activity; wearable monitors AND (calibration OR validation); physical activity AND (calibration OR validation); acceleromet\* thresholds; acceleromet\* (cut-points OR cut-points); energy expenditure AND acceleromet\*; and classification AND physical activity intensities. To check for any further studies meeting the inclusion criteria, the reference list of all the included studies and any systematic reviews on a similar topic were examined.

4. Eligibility criteria {#s0020}
=======================

In order to be included, studies needed to be published in or after the year 2000 in English and generate MVPA cut-points for accelerometry in adults with any chronic clinical condition. Chronic conditions were considered any long-term disease with slow progression ([@b0130]). Book chapters, theses, monographs, dissertations, abstracts, non-human, unpublished and non-English studies were not included. Studies using accelerometers associated with other technologies (e.g. microcontroller), calibrating for healthy population, sedentary behaviour or conditions that required a dispositive for gait (e.g. wheelchair), were excluded.

5. Data extraction and management {#s0025}
=================================

Following the creation of an EndNote X7 (Clarivate Analytics, US) database of potential studies, the lead author screened all the studies based on their titles and abstracts. Where any discrepancies on paper inclusion arose, a second author was available to consult to reach a consensus. All full texts were subsequently independently screened by two authors (MAM and KAM) according to the pre-established criteria. Studies that generated more than one MVPA cut-point were analysed as separate studies since protocols using multiple accelerometers or calibrations in different populations (e.g., different diseases) might lead to different MVPA thresholds. Supplementary information for each study was consulted when available or necessary for data extraction. No additional data was provided after consulting the authors. Data was extracted by the first author (MSB) and cross-checked by two co-authors (KAM and MAM). Further details of the data extraction are presented in [Table 1](#t0005){ref-type="table"}. The risk of bias in individual studies was assessed by two authors (MSB and MAM), independently, using a checklist that was specifically tailored for calibration of accelerometry protocols ([Table 2](#t0010){ref-type="table"}) based on previous literature ([@b0030], [@b0090], [@b0190], [@b0390]). This checklist rates studies as good, fair or poor for six elements of the calibration protocol (sample characteristics, accelerometry settings, criterion, statistical approach for calibration, and statistical approach for validation). Studies scoring poor for all the sections were excluded in order to prevent potentially biased and skewed results ([@b0145]). Inter-rater reliability was determined by using Kappa scores, with 0.8 considered the minimum acceptable inter-rater agreement ([@b0220]). Following the risk assessment, all three authors discussed any discrepancies until a consensus had been reached.Table 1Summary of the extracted from the included studies.Data data extraction fieldInformation extracted*Context and participants*The author, year and sample size of the study; participant characteristics, such as age, health status, height, weight, BMI, ethnicity; and covariates measured, such as self-report questionnaire data, health scales related to disease assessments*Study design and methods used*Any information related to the accelerometer, such as accelerometer model (e.g., number of axes); accelerometer placement (e.g., wrist \[dominant/non-dominant\], hip, chest); accelerometer settings (e.g., epoch, sampling frequency, use of low frequency filter); and data processing decisions (e.g., wear-time criteria) were extracted. Additionally, any information related to the calibration protocol, such as protocol design (e.g., laboratory-based, field-based, daily-life protocol); duration of the protocol; adjustment of specific variables (e.g., age, body mass); performance of individual calibration; criterion anchoring (e.g., energy expenditure, direct observation, heart rate); resting metabolic rate assessment; statistical approach (e.g., ROC-curve analyses, linear regression, machine learning); validation method (e.g., validation, cross-validation leave-one-out, cross-validation k-fold); and assessment for agreement (e.g., Kappa, Bland-Altman)*Findings*The extracted outcomes were protocol design and cut-points. All the extracted protocols were classified in four categories: laboratory-based (walking or running, over-ground or on a treadmill), free-living (assessment of participant routine), daily-life (daily-life activities performed at the research site) and mixed (at least two of laboratory-based, free-living and daily-life) protocols*Quality of the study*Checklist rating for performing calibration for accelerometry in clinical adult populationTable 2Guideline Rating for Performing Calibration for Accelerometry in Clinical Adult Population (checklist).StandardPoorFairGood1. Sample CharacteristicsCalibration study that did not provide any descriptive variables other than age and sexCalibration study that assessed descriptive variables such as height, weight, body mass index and variables specific to the clinical conditionCalibration study that assessed descriptive variables such as height, weight, body mass index, ethnicity, resting metabolic rate and variables specific to the clinical condition2. Accelerometry SettingsStudy just described the accelerometer modelStudy described the accelerometer model, number of axes and placementStudy described the accelerometer model, number of axes, placement, wear-time criteria (in case of free-living protocols), sampling frequency, epoch length and filtering procedures3. Protocol DesignStudy performed the calibration using a laboratory-based protocol composed only by walking or treadmill testStudy used a mixed protocol combining daily-life activities with a laboratory protocol test on a treadmillStudy used a mixed protocol combining daily-life activities with a laboratory protocol test on a treadmill and free-living assessments4. CriterionUsed speed or direct observation to anchor the accelerometry countsUsed heart rate or metabolic equivalent to anchor the accelerometry countsUsed energy expenditure measures, considering resting metabolic rate\* estimation, to anchor the accelerometry counts5. Statistical Approach for CalibrationStudy used group linear regression or individual linear regression to develop the cut-pointsStudy used ROC curve analyses to develop the cut-pointsStudy used machine learning techniques, hierarchical models or multilevel modelling, adjusting for factors related to participant characteristics and to the pathophysiology of the clinical condition to develop the cut-point(s)6. Statistical Approach for ValidationStudy did not perform a validation of the cut-pointsStudy performed a leave-one-out cross-validation of the cut-points and agreement using Bland-Altman or kappa scoreStudy performed a k-fold cross-validation using different samples and activities, determined agreement using Bland-Altman or Kappa score, and estimated the intraclass correlation coefficient, and / or limits of agreement[^1][^2]

A narrative synthesis was performed covering each area of the protocol design: participant information; inclusion of disease-specific factors; accelerometry model and settings; protocol design; criterion; statistical approach for generating and validating MVPA cut-points.

6. Results {#s0030}
==========

A total of 543,741 titles were identified from all databases, with 540,630 titles remaining after the removal of duplicates. Subsequently, the main author applied the eligibility criteria to all 540,630 titles and abstracts, which resulted in 619 articles remaining for full-text assessment. In total, 608 studies were excluded, primarily due the inclusion of healthy populations (279 studies), resulting in 11 studies involving a total of 488 participants aged 24 -- 73 years being included in this review. Descriptive characteristics of the study samples are provided in [Table 3](#t0015){ref-type="table"}. Twenty-three disease-specific MVPA thresholds for six different clinical conditions were identified. For the final synthesis, the six clinical conditions were stratified into either metabolic (n = 4; obesity, type II diabetes mellitus) or neuromusculoskeletal diseases (n = 7; MS, PD, down syndrome, chronic stroke) ([Fig. 1](#f0005){ref-type="fig"}).Table 3Summary of the included studies characteristics.Studies\
*Author, year*Participants\
*Sample size (n)*\
*Sex (male/female)*\
*Health status*\
*Control Group*\
*Age (range or mean ± SD)*\
*Height (mean ± SD)*\
*Weight (range or mean ± SD)*\
*BMI (range or mean ± SD)*\
*Ethnicity*\
*Covariates*Accelerometer\
*Device Model*\
*Number of axes*\
*Placement*\
*Sampling frequency*\
*Filter*\
*Epoch*\
*Monitoring period*\
*Wear time*Calibration Protocol\
*Physiological/*\
*Observational*\
*EE estimation*\
*RMR estimation*\
*Individual calibration*\
*Protocol type*\
*Duration*Statistical Approach\
*Calibration*\
*Validation*\
*Agreement*Outcome\
*Cut-Points*[@b0260]n = 48\
40 females and 8 males\
Multiple Sclerosis (n = 24)\
Control (n = 24)\
43.5 ± 12.2 years\
167.0 ± 11.6 cm\
76.7 ± 19.2 kg\
Demographic scale\
Patient Determined Disease Steps ScaleActiGraph\
Uniaxial\
Right hip\
Epoch: 30 sPhysiological: VO~2~\
RMR: 3.5 ml.kg^−1^\
Individual calibration: no\
Protocol type: laboratory\
Duration: 30 minCalibration: linear regression\
Validation: none\
Agreement: noneCut-points (counts·min^−1^):\
Multiple Sclerosis:\
LPA: \<591\
MPA: 591--6,460\
VPA: \>6,460\
Control:\
LPA: \<1,289\
MPA: 1,289--7,694\
VPA: \>7,694[@b0185]n = 26\
15 females and 11 males\
Overweight/obese/ Type 2 Diabetes Mellitus\
Control = no\
62.6 ± 6.5 years\
*Calibration group (n: 14):*\
Male: 168.07 ± 5.18 cm\
Female: 151.49 ± 8.54 cm\
Male: 80.32 ± 7.21 kg Female: 77.05 ± 21.03 kg\
31 ± 5.17 kg·m^−2^\
Obese: 57.1%\
Overweight: 42.9%\
Caucasians\
HBA1c: 7.2 ± 1.8%\
Insulin: 9.6 ± 4.41 mg·dL^−1^\
HOMA-IR: 1.59 ± 0.71\
*Validation group (n = 12):*\
Male: 162.63 ± 3.54 cm\
Female: 155.1 ± 7.99 cm\
Male: 75.9 ± 16.03 kg\
Female: 72.19 ± 17.58 kg\
29.33 ± 4.85 kg·m^−2^\
Obese: 41.7%\
Overweight: 58.3%\
Caucasians\
HBA1c: 7.34 ± 1.81%\
Insulin: 9.25 ± 4.47 mg·dL^−1^\
HOMA-IR: 1.53 ± 0.72ActiGraph\
Right hip\
Epoch: 60 sPhysiological: VO~2~ and HR\
RMR: 15 min rest\
Individual calibration: none\
Protocol type: laboratory\
Duration: 30 min\
Calibration: Hierarchal Model for equation and ROC for cut-points\
Validation: cross-validation for the regression\
Agreement: concordance correlation coefficientCut-points (counts·min^−1^):\
SED / LPA: 200\
LPA / MPA: 1,240\
MPA / VPA: 2,400[@b0380]n = 24\
20 females and 4 males\
Multiple Sclerosis\
Group with gait disability (n = 10)\
Group without gait disability (n = 14)\
Control: no\
42 ± 11.7 years\
20 Caucasian\
18 graduated from college\
Patient-Determined Disease Steps − 1 (0--4)\
Multiple Sclerosis Walking ScaleActiGraph (7164)\
Uniaxial\
Waist nondominant hip\
10 Hz\
Epoch: 1 sPhysiological: VO~2~\
Individual calibration: none\
Protocol type: laboratory\
Duration: 16 min\
Calibration: linear regression\
Validation: none\
Agreement: noneCut-points (counts·min^−1^):\
Overall:\
MPVA 2371 ± 847\
gait disability: 1,886 ± 739\
without gait disability: 2,717 ± 763[@b0005]n = 42\
31 females and 11 males\
Obesity\
Control: no\
43.2 ± 9.2 years\
172.2 ± 9.1 cm\
118.2 ± 18.2 kg\
39.8 ± 5.7 kg·m^−2^\
Waist circumference: 127.6 ± 13.2 cmActiGraph (GT1M)\
Uniaxial\
Right hip\
Normal Filtering\
Epoch: 10 sPhysiological: VO~2~ and HR\
RMR: 1 h fast -- 10 min in rest\
Individual calibration: yes\
Protocol type: laboratory\
Duration: 40 min\
Calibration: linear regression, linear mixed model and 1. ROC curve with high sensitivity and specificity and 2. ROC with high accuracy.\
Validation: cross-validation\
Agreement: noneCut-points (counts·min^−1^):\
Linear regression:\
3 METS: 720\
Linear mixed model:\
3 METS: 612\
ROC 1:\
3 METS: 1,646\
ROC2:\
3 METS: 1,310\
Linear regression:\
6 METs: 5,779\
Linear mixed model:\
6 METs: 4,980\
ROC1:\
6 METs: 3,061\
ROC2:\
6 METs: 7,220[@b0010]n = 42\
31 females and 11 males\
Obesity\
Control: no\
43.2 ± 9.2 years\
172.2 ± 9.1 cm\
118.2 ± 18.2 kg\
39.8 ± 5.7 kg·m^−2^\
Waist circumference: 127.6 ± 13.2 cmActiGraph (GT1M)\
Uniaxial\
Right hip and left hip (n: 22)\
Normal Filtering\
Epoch: 10 sPhysiological: VO~2~ and HR\
RMR: 1 h fast -- 10 min in rest\
Individual calibration: yes\
Protocol type: laboratory\
Duration: 40 min\
Calibration: Linear regression (individual calibration) and mixed model (group calibration).\
Validation: none\
Agreement: Bland-AltmanCut-points (counts·min^−1^): Individual calibration:\
Right hip:\
MPVA: 1,078 Left hip:\
MPVA: 1,095[@b0015]n = 38\
21 females and 27 males\
Control\
26.3 ± 5.2 years\
171.1 ± 8.2 cm\
73.4 ± 22.6 kg\
24.9 ± 7.4 kg·m^−2^\
n = 17\
Down Syndrome\
9 females\
24.7 ± 6.9 years\
154 ± 79 cm\
76.9 ± 16.8 kg\
32.6 ± 7.7 kg·m^−2^ActiGraph (7164)\
Uniaxial\
Right wrist\
Epoch: 30 sPhysiological: VO~2~\
RMR: 3 h fast -- 6 min rest in sitting position.\
Individual calibration: none\
Protocol type: laboratory\
Duration: 30 min\
Calibration: multilevel modelling.\
Validation: none\
Agreement: Bland-AltmanCut-points (counts·min^−1^): Control:\
self-paced walking: 2,758 ± 1,373\
0.5 m/s: 714 ± 279\
0.75 m/s: 1036 ± 420;\
1 m/s: 1,992 ± 669\
1.25 m/s: 2,743 ± 1,140\
1.5 m/s: 3,185 ± 1568\
3 METs: 1,526\
Down Syndrome:\
self-paced walking: 2888 ± 1468\
0.5 m/s: 862 ± 443\
0.75 m/s: 1,712 ± 747\
1 m/s: 2,708 ± 1,013\
1.25 m/s: 4,052 ± 1862\
1.5 m/s: 5,768 ± 2808\
3 METs: 1,137\
6 METs: 4,525[@b0115]n = 29\
17 females and 12 males\
Obese / overweight\
31.9 ± 9 years\
169.1 ± 8.3 cm\
100.8 ± 23.3 kg\
35.2 ± 7.6 kg·m^−2^\
ѴO~2~: 29.1 ± 11.5 ml·kg^−1^·min^−1^\
n = 25\
Control\
13 males\
26.1 ± 9.4 years\
174.3 ± 8.7 cm\
70 ± 10 kg\
23 ± 2.2 kg·m^−2^\
VO~2~: 40.8 ± 10.2 ml·kg^−1^·min^−1^Actical\
Uniaxial\
Midline of the right tight\
Epoch: 60 s\
Physiological: VO~2~\
RMR: 2 min rest\
Individual calibration: yes\
Protocol type: laboratory\
Duration: 45 min\
Calibration: Linear regression.\
Validation: none\
Agreement: noneCut-points (counts·min^−1^):\
Obese:\
3 METs: 1,923\
6 METs: 4,032\
Control:\
3MET: 1,726\
6MET: 4,117\
[@b0305]n = 86\
76 females and 10 males\
Control\
46.5 ± 10 years\
168.5 ± 8.9 cm\
75.4 ± 16.2 kg\
n = 43\
Multiple Sclerosis\
47.2 ± 9.1 years\
168.2 ± 8.3 cm\
75.7 ± 19.4 kg\
Demographic and exercise history questionnaires\
7DPAR\
26ft GAITRite mat Patient-Determined Steps\
12-item MS walking scaleActiGraph (7164, GT3X)\
Uniaxial and triaxial\
Non-dominant hip\
30 Hz\
Epoch: 15 s\
Physiological: VO~2~\
Individual calibration: yes\
Protocol type: laboratory\
Duration: 20 min\
Calibration: linear regression\
Validation: none\
Agreement: noneCut-points (counts·min^−1^):\
Multiple Sclerosis: MVPA: 1,723 ± 732\
Control:\
MVPA: 2,017 ± 801\
*GT3X:*\
Multiple Sclerosis: MVPA: 1,584 ± 697\
Control: 1,950 ± 852[@b0310]n = 54\
45 females and 9 males\
Multiple Sclerosis\
Control: no\
50.9 ± 9.2 years\
168.3 ± 7.6 cm\
82.3 ± 23 kg\
ActiGraph (GT3X + )\
Triaxial\
Filter: Low frequency extension\
Epoch: 60 sPhysiological: VO~2~\
RMR: 10--15 min rest\
Individual calibration: yes\
Protocol type: laboratory\
Duration:\
Calibration: individual regression\
Validation: none\
Agreement: noneCut-points (counts·min^−1^):\
Vertical axis:\
Overall sample:\
MVPA: 1,754\
Mild and moderate disability:\
MVPA: 1,980\
Severe disability:\
MVPA: 1,185[@b0270]n = 30\
13 females and 17 males\
Parkinson disease\
Control: no\
73 ± 5.4 years\
24.6 ± 3.3 kg·m^−2^\
Unified Parkinson's Disease Rating Scale part II (UPDRS-ADL)\
Freezing of Gait Questionnaire (FOGQ)\
Borg and Perceived Exertion ScaleActiGraph (GT3X + )\
Triaxial\
Waist\
30 Hz\
Filter: normal\
Epoch: 15 sPhysiological: HR and speeds\
RMR\
Individual calibration\
Protocol type: laboratory\
Duration: 9 min\
Calibration: ROC curve\
Validation: leave-one-out cross-validation\
Agreement: Cohen's KappaCut-points (15 s):\
Vertical Axis:\
\<1 ms: \<328\
\>1.3 m/s: \>730\
Vector Magnitude:\
\<1 ms: \<470\>1.3 m/s: \>851[@b0320]n = 28\
10 females and 18 males\
Chronic Stroke - chronic hemiparetic gait\
Control: no\
60.4 ± 1.6 (47--83) years\
31.5 ± 1.1 (19--48) kg·m^−2^\
43% Caucasian\
56% African-american\
6MWT\
Lean mass (kg)Actical\
Uniaxial\
non-paretic hipPhysiological: VO2, HR, karvonen formula (HR reserve).\
RMR: 10 min rest\
Individual calibration: none\
Protocol type: mixed\
Duration: 60 min\
Calibration: Regression analysis\
Validation: none\
Agreement: nonCut-points (counts·min^−1^):\
SED/LPA: 125\
LPA/MPA: 667\
MPA/VPA: 1,546[^3]Fig. 1PRISMA flow presenting the systematic literature search.

Initially the reviewers achieved an inter-rater kappa score of 0.716 for the risk of bias assessment, with the criteria utilised to define RMR the main reasons for disagreement. Subsequently, MSB and MAM resolved discrepancies by discussing each point which resulted in a kappa score of 1 and the criteria to define RMR being specified in the checklist. The majority of the studies had high scores for sample characteristics and accelerometry settings ([Table 4](#t0020){ref-type="table"}), with 5 studies classified as good, five as fair and two as poor for both criteria. Similar results were not found for protocol design, with 10 studies scoring as poor and one as fair. For physiological criterion, 9 studies were classified as fair, 1 as good and 1 as poor. Only two studies scored as good for statistical approach for calibration, with the majority classified as poor (n = 5) and fair (n = 4). Almost all studies were poor (n = 8) for statistical approach for validation, with only 3 studies classified as fair.Table 4Checklist risk of bias assessment results.StudySample CharacteristicsAccelerometry SettingsProtocol DesignCriterionStatistical Approach for CalibrationsStatistical Approach for Validations[@b0260]FairFairPoorFairPoorPoor[@b0380]PoorFairPoorFairPoorPoor[@b0305]GoodGoodPoorFairPoorPoor[@b0310]FairGoodPoorFairPoorPoor[@b0185]GoodPoorPoorFairFairFair[@b0115]FairFairPoorFairFairPoor[@b0005]GoodGoodPoorFairGoodFair[@b0010]GoodGoodPoorFairFairPoor[@b0015]FairFairPoorGoodGoodPoor[@b0270]FairGoodPoorPoorFairFair[@b0320]GoodFairFairFairPoorPoor

Indirect calorimetry was the most common method (n = 10) used to estimate the physiological criterion (e.g. EE, METs or $\overset{˙}{V}$O~2~). Covariates were considered by nine studies, five of which utilised disease-specific assessments (e.g., Multiple Sclerosis Walking Scale). Among the studies including covariates, four either included disease-related factors in the analysis or investigated whether the inclusion of those variables would improve the model adopted for calibration. Four studies also included demographic factors in the analysis. Two studies investigated the relationship of the covariates through correlations with accelerometry derived counts·min^−1^.

7. Accelerometers {#s0035}
=================

Thresholds were developed for 6 different accelerometers ([Table 5](#t0025){ref-type="table"}); the majority were different models of ActiGraph (n = 9) ([@b0005], [@b0010], [@b0015], [@b0260], [@b0270], [@b0300], [@b0310], [@b0380], [@b0185]) with the others using Actical ([@b0115], [@b0320]). Seventeen of the MVPA cut-points were developed using a uni-axial accelerometer and six using a tri-axial accelerometer. The hip was the most common placement, adopted by nine studies to develop 22 MVPA cut-points. Nine of the MVPA cut-points were developed with the accelerometer placed on the right hip ([@b0005], [@b0010], [@b0115], [@b0185], [@b0260]), seven on non-dominant hip ([@b0300], [@b0310]), one on non-paretic hip ([@b0320]), one on both hips ([@b0010]), two on the left hip ([@b0010]). One study placed the accelerometer on the right wrist ([@b0015]) and one did not specify the side ([@b0270]). Reported sampling frequency varied from 10 Hz ([@b0380]) to 30 Hz ([@b0270], [@b0300], [@b0310]), although eight studies did not report the sampling frequency used ([@b0005], [@b0010], [@b0015], [@b0115], [@b0185], [@b0260], [@b0310], [@b0320]). Furthermore, only four studies described how they filtered the accelerometer data, with three ([@b0005], [@b0010], [@b0270]) using the standard filtering provided by the accelerometer software and one ([@b0310]) applying the low-filtering extension provided by ActiLife software. A wide variety of epoch lengths were used to develop the MVPA cut-points, with five studies using 60 s epochs ([@b0115], [@b0185], [@b0310], [@b0320], [@b0380]), followed by one using 10 s ([@b0010]), two studies using 15 s ([@b0270], [@b0300], [@b0310]) and two using 30 s epochs ([@b0015], [@b0260]). The epoch length was extracted from MVPA cut-point unit (i.e. counts·min^−1^, counts per 15 s) when not specified in the methodology ([@b0270]).Table 5Summary of Accelerometer Models Calibrated in the Included Studies.Name/ModelManufacturerDimensions (Weight and Size)Memory CapacityAxisFrequency SamplingActiGraph 7164 (CSA)ActiGraph LLC Pensacola, FL45,5g\
5.1 × 4.1 × 1.5 cm22 days of data with 60 s epochUniaxial10 HzGT1M ActiGraphActiGraph LLC Pensacola, FL27 g\
3.8 × 3.7 × 1.8 cm378 days using 60 s epochBiaxial30 HzActiGraph GT3XActiGraph LLC Pensacola, FL27 g\
3.8 × 3.7 × 1.8 cm378 days using 60 s epochTriaxial30 HzActiGraph GT3X+ActiGraph LLC Pensacola, FL19 g\
4.6 × 3.3 1.5 cm38 days using 100 HzTriaxial30--100 HzActiGraph wGT3X+ActiGraph LLC Pensacola, FL19 g\
4.6 × 3.3 1.5 cm38 days 100 HzTriaxial30--100 HzActicalMini-Mitter Sunriver, OR17.5 g\
2.8 × 2.7 × 1.0 cm45d using 60 s epochUniaxial32 Hz

8. Calibration protocol settings {#s0040}
================================

Laboratory-based protocols were utilised in 10 studies ([@b0005], [@b0010], [@b0015], [@b0260], [@b0270], [@b0300], [@b0310], [@b0385], [@b0115], [@b0185]), with only one study ([@b0185]) applying a mixed protocol. Indirect calorimetry was performed by 10 of the studies ([@b0005], [@b0010], [@b0015], [@b0115], [@b0185], [@b0260], [@b0300], [@b0310], [@b0320], [@b0380]), with one study ([@b0270], [@b0320]) using both indirect calorimetry and HR and another using speed ([@b0270]) and the duration of the protocol varied from 9 to 60 min. Indirect calorimetry was utilised as the physiological criterion by the majority of studies (n = 10). Specifically, six studies derived Metabolic Equivalents of Task (MET) from oxygen uptake (VO~2~), whereas four studies used the VO~2~ itself to determine the relationship with accelerometry counts. Four studies performed an individual calibration ([@b0010], [@b0115], [@b0300], [@b0310]), five performed a group calibration ([@b0260], [@b0270], [@b0320], [@b0380], [@b0185]) and one study performed both ([@b0010]).

9. Statistical approach {#s0045}
=======================

Linear regression was the most common technique employed to generate eight MVPA cut-points in adult clinical populations ([@b0005], [@b0010], [@b0260], [@b0300], [@b0310], [@b0320], [@b0380], [@b0385]), followed by hierarchical modelling, generating four MVPA cut-points ([@b0005], [@b0010], [@b0015], [@b0185]), and receiver operating characteristic (ROC) analysis, developing five MVPA cut-points ([@b0005], [@b0270], [@b0115]). Thus, one study ([@b0005]) applied two different ROC models; the first model prioritized higher sensitivity (true positives/total positives) and specificity (true negatives/total negatives), whilst the second model used overall accuracy (true positives and true negatives/total positives and negatives). Ten studies ([@b0005], [@b0010], [@b0015], [@b0115], [@b0185], [@b0260], [@b0300], [@b0310], [@b0380]) did not perform any kind of validation and one performed a leave-one-out cross-validation ([@b0270]). Furthermore, most of the studies did not perform any agreement assessment (n = 8) ([@b0005], [@b0010], [@b0185], [@b0260], [@b0300], [@b0310], [@b0320], [@b0380]); one study performed Bland-Altman ([@b0015]) and one calculated the Kappa Score ([@b0270]).

10. Outcome {#s0050}
===========

All the disease-specific MVPA cut-points extracted from the included studies were integrated to a 60 s epoch to allow comparison between thresholds when not available in this format ([Table 6](#t0030){ref-type="table"}). Most studies presented their cut-points in counts·min^−1^, despite using different epoch lengths for processing the activity counts. Disease-specific cut-points of MVPA varied from a minimum of 612 counts·min^−1^ to a maximum of 6,460 counts·min^−1^.Table 6Summary of MVPA Disease-specific Cut-points.Disease (n\*)StudyReason for splitCut-points MVPA (original)Cut-points MVPA converted to counts.min^−1a^Criterion ValidityMultiple Sclerosis **(7)**[@b0260]N/A6460 (counts·min^−1^)N/AN/A[@b0380]No Gait-disability Group2717 (counts·min^−1^)N/AN/A[@b0380]Overall Group (gait and non-gait-disability)2371 (counts·min^−1^)N/AN/A[@b0380]Gait-disability Group1886 (counts·min^−1^)N/AN/A[@b0305]ActiGraph 71641723 (counts·min^−1^)N/AN/A[@b0305]ActiGraphGT3X1584 (counts·min^−1^)N/AN/A[@b0310]Overall Group (gait and non-gait-disability)1745 (counts·min^−1^)N/AN/A[@b0310]Gait-disability Group1185 (counts·min^−1^)N/AN/A[@b0310]No Gait-disability Group1980 (counts·min^−1^)N/AN/AOverweight/obesity/Type 2 Diabetes Mellitus **(10)**[@b0185]N/A2400 (counts·min^−1^)N/AConcordance Correlation Coefficient: 0.8[@b0115]N/A4032 (counts·min^−1^)N/AN/A[@b0005]ROC 11646 (counts·min^−1^)N/AN/A[@b0005]ROC 21310 (counts·min^−1^)N/AN/A[@b0010]Individual Calibration/Linear Regression1151 (counts·min^−1^)N/ABland-Altman/LOA[@b0010]Linear Regression/Left Hip1095 (counts·min^−1^)N/ABland-Altman/LOA[@b0010]Linear Regression/Right Hip1078 (counts·min^−1^)N/ABland-Altman/LOA[@b0005]OLR/Right Hip720 (counts·min^−1^)N/AN/A[@b0005]MIX REG/Left Hip685 (counts·min^−1^)N/ABland-Altman/LOA[@b0005]MIX REG/Right Hip612 (counts·min^−1^)N/AN/ADown Syndrome **(1)**[@b0015]N/A1137 (counts·min^−1^)N/ABland-Altman/LOAParkinson disease **(2)**[@b0270]N/A730 (counts·15 s^−1^)2980Cross-validation: 74%--64% of agreement; Kappa Score: 0.79 for y axis and kappa score: 0.69 for VM.[@b0270]851 (counts·15 s^−1^)3404Chronic Stroke **(1)**[@b0320]N/A1546 (counts·min^−1^)N/AN/A[^4][^5]

11. Discussion {#s0055}
==============

In total, 11 studies generating 23 MVPA cut-points in clinical conditions revealed a broad range of MVPA cut-points. Key recommendations for future studies are to include a variety of free-living activities that are applicable to the specific disease-population, of various intensities, and to ensure that a robust measure of EE and precise estimation of RMR are included to account for disease-related alterations.

12. Calibration protocol for clinical populations {#s0060}
=================================================

Numerous factors should be considered in the development of a calibration protocol for clinical populations, including the inclusion of participant demographics and disease-related factors. Another key consideration in the development of cut-points for clinical populations is the addition of a physiological criterion to the calibration protocol, particularly related to energetic cost. Specifically, some conditions might be associated with an alteration in the daily total EE. This variation is likely to occur due to many factors, including impaired biomechanics (e.g., neuromusculoskeletal disorders), higher energetic cost of breathing (e.g., respiratory conditions) and disease severity and treatments (e.g., medications; ([@b0035], [@b0285], [@b0300], [@b0330]). Thus, numerous factors in addition to PA contribute to total EE, such as the thermal effect of food intake and RMR. Indeed, indirect calorimetry was shown to overestimate EE when the RMR was not properly assessed ([@b0080]). Therefore, RMR estimation is highly recommended to avoid bias, particularly as it was shown to be altered in many clinical conditions ([@b0015], [@b0020], [@b0110], [@b0200], [@b0245], [@b0265], [@b0325], [@b0395]). Alternatively, METs can be used to estimate EE; Serra et al. ([@b0320]) found METs to be the strongest predictor of activity counts, despite explaining only 65% of the accelerometer activity counts. Thus, most of the included studies derived MET values from a measure of oxygen uptake, which arguably would encompass any possible alteration in energetic cost arising from the disease. However, careful consideration must be given when using METs due to the controversial nature of this method and its failure to represent clinical subgroups ([@b0230]). Indeed, the standard MET value of 3.5 ml·kg^−1^·min^−1^ was developed based on healthy populations and therefore does not reflect pathological, biomechanical, metabolic and respiratory adaptations which are common in many clinical conditions ([@b0050]).

13. Accelerometer setting and analysis description {#s0065}
==================================================

Whilst hip was the most popular choice among the included studies ([@b0005], [@b0010], [@b0115], [@b0185], [@b0260], [@b0300], [@b0310], [@b0320]), the best location for monitor placement in clinical populations is unclear. Indeed, comparisons of hip- and wrist-generated thresholds demonstrated great variability which may be explained by biomechanical differences related to dominance ([@b0010]) or functional adaptations due to clinical conditions ([@b0160], [@b0180]). For example, in PD, freezing of gait can lead to a rapid trembling in the legs, which would be more efficiently measured by an accelerometer placed on the lower limb ([@b0355]). Similarly, other conditions affecting the gait biomechanics might benefit from hip or lower limb placements, as demonstrated under a free-living protocol for chronic stroke and MS patients ([@b0290], [@b0335]).

The choice of accelerometry settings and signal processing should be described in the calibration protocol to allow comparability between studies and generalisability of the developed cut-points ([@b0045]). Nonetheless, five of the included studies did not report the sampling frequency and filtering methods used ([@b0015], [@b0115], [@b0185], [@b0260], [@b0320]). The most popular choice of epoch was 60 s ([@b0115], [@b0185], [@b0300], [@b0310], [@b0320], [@b0380]), with the majority of studies presenting MVPA in counts·min^−1^. Alternatively, the choice of 1 or 5 s epochs is appropriate to capture short bursts of activities and could be a suitable choice for free-living protocols or for analyses utilising pattern recognition ([@b0105], [@b0345]). Whilst counts·min^−1^ are commonly used, the units are somewhat arbitrary and lack direct practical meaning and transparency due to their proprietary nature ([@bib397]). Indeed, the brand-specific units limit inter-study comparisons. In contrast, the use of raw acceleration signals allow more complex analyses and, consequently, higher prediction accuracy ([@b0255]).

14. Protocol design {#s0070}
===================

The calibration protocols were classified into four categories: laboratory-based protocols that involved walking or running on a treadmill; free-living protocols that assessed participants during their daily routines; daily-life protocols that involved daily-life activities in the laboratory and mixed protocols that utilised more than one of the previously described protocols. A free-living protocol is widely considered the most appropriate for calibration as it determines the relationship between EE and PA in an ecologically valid manner ([@b0090], [@b0195]). Despite that, almost all the studies in the neuromusculoskeletal disease group ([@b0015], [@b0260], [@b0270], [@b0300], [@b0310], [@b0380]) utilised over-ground walking protocols. Likewise, almost all of the studies in metabolic disease populations ([@b0005], [@b0010], [@b0115], [@b0185]) performed treadmill walking protocols, with only one study encompassing jogging. A limitation of such walking protocols is that they are unlikely to provide a fair classification of activities beyond those of locomotion ([@b0070]). In addition, studies suggest that individuals with chronic stroke and PD are more prone to adopt a different strategy to increase gait speed when walking on the treadmill ([@b0155], [@b0375]). During treadmill ambulation, the lack of visual cues and a moving floor results in a cautious gait, with individuals adopting slower speeds and increased stride length compared to overground walking ([@b0155], [@b0375]). As such, the use of treadmill to calibrate for such populations may result in a misrepresentation of their gait during daily-life and should be considered with caution. Alternatively, a free-living protocol would be the ideal framework to provide a more ecologically valid measure of PA ([@b0390]) in clinical populations.

15. Statistical approach {#s0075}
========================

The statistical approach adopted to translate activity counts and EE into cut-points could substantially impact the derived thresholds. For example, whilst linear regression has been most widely used ([@b0005], [@b0010], [@b0260], [@b0300], [@b0310], [@b0320], [@b0380]), it assumes that the relationship between activity counts and metabolic data (i.e. VO~2~, METs) is linear. To address this issue, recent calibration studies have incorporated more flexible statistical methods, such as ROC analysis, hierarchical models, and machine learning ([@b0025], [@b0075], [@b0090], [@b0250]). However, in the context of clinical populations, it is pertinent to note that ROC analysis does not allow adjustment for clinical factors and may therefore not be an optimal approach.

Machine learning and pattern recognition have been identified as the optimal methods for classifying PA ([@b0040], [@b0340], [@b0350], [@b0390]). A recent systematic review highlighted the high predictive accuracy of laboratory-calibrated protocols using machine learning models ([@b0085]), with hidden markov models ([@b0280]), decision trees ([@b0210]) and artificial neural networks ([@b0350]) the most common models used to estimate PA from raw accelerometry signals. Indeed, the use of such models improved PA prediction, overcoming the inherent limitations of using static epoch lengths ([@b0255]). Whilst promising, the use of machine learning to estimate PA from raw accelerations is still in the early phases of development. Specifically, the reproducibility of machine learning approaches in free-living settings requires further investigation ([@b0150]). Additionally, machine learning models often require considerably sized training data sets, particularly deep learning, which might be a challenge when using indirect calorimetry ([@b0205]). Future studies calibrating accelerometry for clinical populations should consider using machine learning in order to achieve higher prediction accuracy and promote advancements in the field. However, it is noteworthy that even complex statistical approaches such as pattern recognition would still require an optimised calibration protocol in order to ensure high prediction accuracy. In addition, other statistical approaches should also be considered, such as probability analysis which has been employed to translate activity counts into PA behavioural data in mental illness patients ([@b0060]).

Cross-validation establishes the validity of the developed cut-points and verifies that the thresholds are applicable across any participant of similar age and health status to the sample it was generated from. Whilst it is recommended that a cross-validation should be conducted utilising an independent sample and different activities ([@b0390]), the use of a leave-one-out-approach can also be considered. For example, [@b0270] used a leave-one-out approach to cross-calibrate the specific PD cut-points. Additionally, a measure of agreement should be performed in addition to a cross-validation ([@b0185]), and the cross-validation should be applied after developing the thresholds and not as a robustness check prior to the analysis ([@b0005]). Future studies should continue to cross-validate the disease-specific thresholds to ensure their reliability and validity across different protocols and clinical stages.

16. Outcome: MVPA cut-points {#s0080}
============================

Disease-specific cut-points are essential in understanding and promoting PA in clinical populations. The majority of the MVPA cut-points developed for clinical populations were different to those previously developed for healthy adults ([@b0100]); disease-specific MVPA cut-points varied greatly, from 612 counts·min^−1^ to 6460 counts·min^−1^, even within the same condition. Indeed, [@b0320] developed Actical MVPA cut-points for stroke patients that were equivalent to LPA cut-points for general population. This large variability can be attributed to the occurrence of gait impairment at advanced stages of the disease, in addition to differences in treatments and medications. However, a control group is warranted in order to ascertain whether any variation in the cut-points is caused by the pathophysiology of the disease or differences in the calibration protocol. Indeed, whilst a control group is highly beneficial in the interpretation of the findings of each study, cut-points previously established for general populations could be used when necessary to investigate whether the use of the disease-specific cut-points enhances the predictive accuracy ([@b0140], [@b0365]).

17. Strengths and limitations {#s0085}
=============================

It is important to acknowledge that the search protocol was developed with a subject-specific librarian, following a rigorous iterative process. Specifically, initial pilot searches were conducted to assess the feasibility of the initial criteria and search terms. Revisions were subsequently made to the outcomes, risk of bias assessment and final analyses. Moreover, extensive screening was performed by the first author to capture all calibration studies, irrespective of healthy or clinical status, to ensure that no clinical calibration studies were missed. Whilst this review is associated with numerous strengths, there are, nonetheless, limitations. Firstly, only studies generating MVPA cut-points were included; whilst cut-points are still widely used in PA research, major limitations associated with this practice should be acknowledged. The large variability of intensity-related cut-points also occurs among general population ([@b0295]), causing what [@bib398] described as the 'cut-point conundrum'. This discrepancy is multifactorial, arising in part from the lack of standardization of calibration protocols and broad range of statistical approaches applied to reduce accelerometer data to cut-points. It is also important to acknowledge the high risk of bias encountered within the included studies which limits our conclusions. Finally, it is noteworthy that the present recommendations were based on a relatively small range of clinical conditions, further demonstrating the need for more population-specific calibration protocols.

18. Conclusion {#s0090}
==============

This systematic review highlights the large variability in MVPA cut-points developed for clinical populations. Indeed, a lack of standardisation in the protocol design, as well as the statistical approach, makes it impossible to compare disease-specific cut-points to those generated for healthy populations. To ensure ecological validity, future calibration protocols should incorporate a large variety of free-living activities, of various intensities, instead of protocols composed predominantly of walking. Moreover, future research should ensure a robust measure of EE is adopted as the criterion measure for accelerometry, as well as a precise estimation of RMR. Studies incorporating a control group and utilising cross-validation of the developed clinical thresholds are warranted. Finally, whilst standardization is necessary, it is highly recommended that future studies consider the pathophysiology of the disease when designing the protocol.
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[^1]: ROC: receiver operating characteristic.

[^2]: \*The criteria for a valid resting metabolic rate estimation was a minimum of 15 mins of steady state, preferably adopting the formula of de Weir (1948).

[^3]: SED: sedentary activity, LPA: light physical activity, MPA: moderate physical activity, VPA: vigorous physical activity, MVPA: moderate to vigorous physical activity, RMR: resting metabolic rate, VO~2~: oxygen uptake, HR: heart rate, ROC: receiver operating characteristic, ROC 1: ROC with best sensitivity and specificity, ROC 2: ROC with best accuracy definition, MET: metabolic equivalent.

[^4]: ROC: receiver operating characteristic, ROC 1: Roc with best sensitivity and specificity, ROC 2: ROC with better accuracy definition, OLR: Ordinary Linear Regression, MIX REG: Linear Mixed Model Regression. LOA: limits of agreement.

[^5]: ^a^Converted when not available.
